...
首页> 外文期刊>Clinical Science >LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention
【24h】

LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to microvascular endothelial cells: mitigation by statin intervention

机译:高胆固醇血症和阿尔茨海默氏病患者的LDL脂质对微血管内皮细胞具有炎症作用:他汀类药物干预可缓解

获取原文
获取原文并翻译 | 示例
           

摘要

Elevated low-density lipoprotein (LDL) concentration in mid-life increases the risk of developing Alzheimer's disease (AD) in later life. Increased oxidized LDL (oxLDL) modification and nitration is observed during dementia and hypercholesterolaemia. We investigated the hypothesis that statin intervention in mid-life mitigates the inflammatory effects of oxLDL on the microvasculature. Human microvascular endothelial cells (HMVECs) were maintained in transwells to mimic the microvasculature and exposed to patient and control LDL. Blood was obtained from statin-naive, normo- and hyper-lipidaemic subjects, AD with vascular dementia (AD-plus) and AD subjects (n=10/group) at baseline. Only hyperlipidaemic subjects with normal cognitive function received 40 mg of simvastatin intervention/day for 3 months. Blood was re-analysed from normo- and hyper-lipidaemic subjects after 3 months. LDL isolated from statin-naive hyperlipidaemic, AD and AD-plus subjects was more oxidized (agarose gel electrophoretic mobility, protein carbonyl content and 8-isoprostane F2 alpha) compared with control subjects. Statin intervention decreased protein carbonyls (2.5 +/- 0.4 compared with 3.95 +/- 0.2 nmol/mg; P<0.001) and 8-isoprostane F2 alpha (30.4 +/- 4.0 pg/ml compared with 43.5 +/- 8.42 pg/ml; P<0.05). HMVEC treatment with LDL-lipids (LDL-L) from hyperlipidaemic, AD and AD-plus subjects impaired endothelial tight junction expression and decreased total glutathione levels (AD; 18.61 +/- 1.3, AD-plus; 16.5 +/- 0.7 nmol/mg of protein) compared with untreated cells (23.8 +/- 1.2 compared with nmol/mg of protein). Basolateral interleukin (IL)-6 secretion was increased by LDL-L from hyperlipidaemic (78.4 +/- 1.9 pg/ml), AD (63.2 +/- 5.9 pg/ml) and AD-plus (80.8 +/- 0.9 pg/ml) groups compared with healthy subject lipids (18.6 +/- 3.6 pg/ml). LDL-L isolated after statin intervention did not affect endothelial function. In summary, LDL-L from hypercholesterolaemic, AD and AD-plus patients are inflammatory to HMVECs. In vivo intervention with statins reduces the damaging effects of LDL-L on HMVECs.
机译:中年时低密度脂蛋白(LDL)浓度升高会增加以后发生阿尔茨海默氏病(AD)的风险。在痴呆和高胆固醇血症期间观察到增加的氧化LDL(oxLDL)修饰和硝化作用。我们调查了中年他汀类药物干预可减轻oxLDL对微脉管系统的炎症影响的假设。将人微血管内皮细胞(HMVEC)保留在Transwell中以模拟微脉管系统,并暴露于患者和对照LDL。从未接受他汀类药物,常脂和高脂血症的受试者,患有血管性痴呆的AD(AD加)和处于基线的AD受试者(n = 10 /组)获得血液。仅具有正常认知功能的高脂血症受试者每天接受40毫克辛伐他汀干预,持续3个月。 3个月后,从正常和高脂血症患者中重新分析血液。与对照组相比,从未经他汀类药物治疗的高脂血症,AD和AD加受试者中分离出的LDL的氧化程度更高(琼脂糖凝胶电泳迁移率,蛋白质羰基含量和8-异前列腺素F2α)。他汀类药物的干预减少了蛋白质的羰基蛋白含量(2.5 +/- 0.4,而3.95 +/- 0.2 nmol / mg; P <0.001)和8-异前列腺素F2α(30.4 +/- 4.0 pg / ml,而43.5 +/- 8.42 pg / ml ml; P <0.05)。用高脂血症,AD和AD +受试者的LDL-脂质(LDL-L)进行HMVEC治疗可损害内皮紧密连接表达并降低总谷胱甘肽水平(AD; 18.61 +/- 1.3,AD-plus; 16.5 +/- 0.7 nmol /毫克蛋白)与未处理的细胞相比(与nmol / mg蛋白相比为23.8 +/- 1.2)。高脂血症(78.4 +/- 1.9 pg / ml),AD(63.2 +/- 5.9 pg / ml)和AD-plus(80.8 +/- 0.9 pg / ml)的LDL-L增加了基底外侧白介素(IL)-6的分泌毫升)组与健康受试者的脂质(18.6 +/- 3.6 pg / ml)进行比较。他汀类药物干预后分离出的LDL-L不会影响内皮功能。总之,来自高胆固醇血症,AD和AD +患者的LDL-L对HMVEC具有炎症性。他汀类药物的体内干预减少了LDL-L对HMVEC的破坏作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号